Commentary

The Psoriasis Plot Thickens [editorial]

Over the last several years dermatologists have become increasingly aware of a growing body of data suggesting that psoriasis is associated with systemic comorbidities including metabolic syndrome and increased risk for cardiovascular disease. Metabolic syndrome generally is defined by the presence of or treatment of at least 3 of the following 5 criteria: hypertension, insulin resistance, decreased high-density lipoprotein, hypertriglyceridemia, and central obesity. We have witnessed a transformation in the way we approach psoriasis. In the past, psoriasis was mainly viewed as a cutaneous concern; however, it is now viewed and treated as a systemic inflammatory condition, which deserves a multidisciplinary approach.


 

Recommended Reading

Meta-Analysis Shows 75% Increased Risk Herpes Zoster With Anti-TNF
MDedge Dermatology
Clinical Trials May Overestimate Benefits of Psoriasis Drugs
MDedge Dermatology
Lupus Severity May Contribute Significantly to Heart Damage
MDedge Dermatology
Genotypes in ANCA-Associated Vasculitis May Guide Therapy
MDedge Dermatology
Subclinical Enthesitis Is More Common in Psoriatic Arthritis
MDedge Dermatology
Collagenase Might Be a First-Line Treatment for Dupuytren's Contractures
MDedge Dermatology
Most Psoriasis Patients at Risk for Heart Disease
MDedge Dermatology
Systemic Psoriasis Therapies Cut MI Risk
MDedge Dermatology
Rheumatologic Serologies Can Be a Confounding Quagmire
MDedge Dermatology
Use of Bovine-Based Collagen Ointment in the Treatment of Plaque Psoriasis: An Open-Label, Pilot, Observational Clinical Study of 12 Patients
MDedge Dermatology